← Back to headlines
Genmab Misses Q4 Revenue and EPS Estimates, Initiates FY26 Outlook
Genmab reported a GAAP EPS of $15.37 and revenue of $3.72 billion, missing estimates by $50 million, and has initiated its FY26 outlook.
18 Feb, 04:53 — 18 Feb, 04:53
